Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

JR Molina, P Yang, SD Cassivi, SE Schild… - Mayo clinic …, 2008 - Elsevier
Lung cancer is the leading cause of cancer-related mortality not only in the United States but
also around the world. In North America, lung cancer has become more predominant among …

Targeting apoptosis pathways in cancer therapy

IM Ghobrial, TE Witzig, AA Adjei - CA: a cancer journal for …, 2005 - Wiley Online Library
Apoptosis, or programmed cell death, is a mechanism by which cells undergo death to
control cell proliferation or in response to DNA damage. The understanding of apoptosis has …

Blocking oncogenic Ras signaling for cancer therapy

AA Adjei - Journal of the National Cancer Institute, 2001 - academic.oup.com
The Ras gene product is a monomeric membrane-localized G protein of 21 kd that functions
as a molecular switch linking receptor and nonreceptor tyrosine kinase activation to …

[PDF][PDF] Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

RS Go, AA Adjei - Journal of Clinical Oncology, 1999 - Citeseer
Purpose: To review the pharmacodynamics, pharmacokinetics, toxicities, and relative
clinical activities of cisplatin and carboplatin. Through a search of the MEDLINE database …

[PDF][PDF] Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

J Rinehart, AA Adjei, PM LoRusso… - Journal of clinical …, 2004 - Citeseer
Purpose This multicenter, open-label, phase II study was undertaken to assess the antitumor
activity and safety of the oral mitogen-activated extracellular signal regulated kinase kinase …

[HTML][HTML] Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY …

AA Adjei, RB Cohen, W Franklin, C Morris… - Journal of clinical …, 2008 - ncbi.nlm.nih.gov
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated
Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced …

Small cell lung cancer

T Sher, GK Dy, AA Adjei - Mayo Clinic Proceedings, 2008 - Elsevier
Small cell lung cancer accounts for approximately 15% of bronchogenic carcinomas. It is the
cancer most commonly associated with various paraneoplastic syndromes, including the …

Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor

Y Zhao, AA Adjei - The oncologist, 2015 - academic.oup.com
Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during
human development and reproduction; however, aberrant regulation of angiogenesis is also …

[HTML][HTML] Control of confounding and reporting of results in causal inference studies. Guidance for authors from editors of respiratory, sleep, and critical care journals

DJ Lederer, SC Bell, RD Branson… - Annals of the …, 2019 - atsjournals.org
The views and recommendations made in this document do not represent the official
position of any publisher or professional medical society. This document has not been …

Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003

P Yang, MS Allen, MC Aubry, JA Wampfler, RS Marks… - Chest, 2005 - Elsevier
Study objectives To improve the current understanding of the etiology and natural history of
primary lung cancer, we need to study the dynamic changes of clinical presentation and …